Down-regulation of Epidermal Growth Factor Receptors by Nerve Growth Factor in PC12 Cells Is p140trk-, Ras-, and Src-dependent*

(Received for publication, October 8, 1996, and in revised form, February 17, 1997)

Philip Lazarovici Dagger , Mari Oshima , Davidit Shavit Dagger , Makoto Shibutani , Hao Jiang , Mariam Monshipouri , Donald Fink §, Vilen Movsesyan and Gordon Guroff par

From the Section on Growth Factors, NICHD, National Institutes of Health, Bethesda, Maryland 20892 and § Center of Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENT
REFERENCES


ABSTRACT

Nerve growth factor (NGF) treatment causes a profound down-regulation of epidermal growth factor receptors during the differentiation of PC12 cells. This process is characterized by a progressive decrease in epidermal growth factor (EGF) receptor level measured by 125I-EGF binding, tyrosine phosphorylation, and Western blotting. Treatment of the cells with NGF for 5 days produces a 95% reduction in the amount of [35S]methionine-labeled EGF receptors. This down-regulation does not occur in PC12nnr5 cells, which lack the p140trk NGF receptor. However, in PC12nnr5 cells stably transfected with p140trk, the NGF-induced heterologous down-regulation of EGF receptors is reconstituted in part. NGF-induced heterologous down-regulation, but not EGF-induced homologous down-regulation of EGF receptors, is blocked in Ras- and Src-dominant-negative PC12 cells. Treatment with either pituitary adenylate cyclase-activating peptide (PACAP) or staurosporine stimulates neurite outgrowth in PC12 cell variants, but neither induces down-regulation of EGF receptors. NGF treatment of PC12 cells in suspension induces down-regulation of EGF receptors in the absence of neurite outgrowth. These results strongly suggest a p140trk-, Ras- and Src-dependent mechanism of NGF-induced down-regulation of EGF receptors and separate this process from NGF-induced neurite outgrowth in PC12 cells.


INTRODUCTION

PC12 cells, derived from a rat pheochromocytoma, have been extensively used as a model of neuronal differentiation (1), because the cells acquire the phenotype of sympathetic neurons and stop dividing in response to nerve growth factor (NGF)1 (2). In PC12 cells, NGF interacts with two distinct plasma membrane receptor proteins: p75NGFR, a cysteine-rich glycoprotein having a relatively low affinity for NGF (3), and p140trk, a receptor tyrosine kinase activated by NGF, which binds NGF with high affinity and mediates many of the biological activities of this neurotrophin (4). The binding of NGF to the p140trk receptor stimulates rapid tyrosine autophosphorylation of the receptor and activation of several signal-transducing proteins (4). Activated p140trk receptors bind to and tyrosine phosphorylate the signaling substrates phospholipase Cgamma 1, phosphatidylinositol-3 kinase, and Src homologous collagen protein (4), resulting in their activation. The latter stimulates Ras activity which subsequently activates a series of serine/threonine kinases including B-Raf, myelin basic protein kinase kinase, the Erks, and p90rsk (4). This Ras-Erk pathway plays a major role in the activation of transcriptional events by NGF and in NGF-induced neuronal differentiation (5), as illustrated by inhibition of NGF actions upon expression of dominant-negative Ha-Ras (Asn-17) proteins (6, 7). In addition a role for pp60c-src in NGF actions has been suggested (5) by experiments involving the expression of a dominant-interfering kinase-inactive Src (8).

PC12 cells also express plasma membrane receptors for epidermal growth factor (EGF) (9, 10), a mild mitogen for these cells (9). PC12 cells treated with NGF exhibit an attenuated response to EGF (9) because EGF receptors are down-regulated (9, 11). The cellular mechanisms that mediate NGF-induced EGF receptor down-regulation are unknown and represent an interesting question in neuronal development. The existence of functional receptors for both NGF and EGF on PC12 cells and the recent advances in understanding the signaling pathways activated by these receptors make these cells a useful model for the study of cross-regulation between NGF and EGF receptors during differentiation.

In this study, we have used a number of PC12 variant cell lines with different levels of p140trk (12, 13) and EGF receptor expression and dominant-negative Ras (7, 14, 15) or Src (5, 6, 8) PC12 transfectants in an attempt to elucidate the molecular mechanisms of the receptor cross-talk required by NGF to down-regulate EGF receptors. Our findings implicate the involvement of p140trk-, Ras-, and Src-dependent signaling pathways in NGF-induced down-regulation of EGF receptors while demonstrating an independence of this cellular process from NGF-induced neurite outgrowth.


EXPERIMENTAL PROCEDURES

Materials

Mouse NGF, EGF, bovine brain-derived acidic FGF and basic FGF, and rat collagen type II were purchased from Collaborative Biochemicals (Bedford, MA). Dexamethasone, poly-L-lysine, and myelin basic protein were purchased from Sigma. K-252a and staurosporine were prepared at Kyowa Hakko Kogyo, Ltd. (Tokyo, Japan). Pituitary adenylate cyclase-activating polypeptide (rat PACAP-38) and the PACAP receptor antagonist PACAP (6-38) were purchased from Peninsula Laboratories (Belmont, CA). Heparin was obtained from Hepar (Franklin, OH). The monoclonal anti-phosphotyrosine (4G10) and anti-EGF receptor (6F1) antibodies were purchased from Upstate Biotechnology Inc. (Lake Placid, NY) and Medical and Biological Laboratories, Co. Ltd (Nagoya, Japan), respectively. The polyclonal anti-trkA (C14), anti-Src, anti-Ras, and anti-Erk1 antibodies were products of Santa Cruz Biotechnology Inc. (Santa Cruz, CA). The polyclonal anti-EGF receptor antibody 1210 was raised against a 12-amino acid peptide derived from the intracellular domain of the EGF receptor (16). Rabbit anti-neurofilament M C-terminal polyclonal antibody was purchased from Chemicon International Inc. (Temecula, CA). Murine 125I-EGF (specific activity 180 µCi/µg) and 125I-NGF (specific activity 70.6 µCi/µg) were obtained from DuPont NEN. [3H]Thymidine (specific activity, 85 Ci/mmol) and [gamma -32P]ATP were purchased from Amersham Corp. 125I-FGF was prepared as described previously (17).

Cell Culture

PC12 cells were grown in Dulbecco's modified Eagle's medium (DMEM; Life Technologies, Inc.) supplemented with 7% fetal bovine serum, 7% horse serum, 100 µg/ml streptomycin, and 100 units/ml penicillin, all from Life Technologies, Inc. (11). In all experiments involving extended treatment with NGF, the medium was changed, and fresh NGF was added every other day. PC12nnr5 cells were grown in collagen-coated tissue culture dishes in RPMI 1640 medium (Life Technologies, Inc.) supplemented with 10% horse serum and 5% fetal bovine serum (13). 6.24 cells, a clone of PC12 overexpressing human p140trk, were grown under the same conditions as PC12 cells in the presence of 200 µg/ml G418 (Life Technologies, Inc.) (12). During the down-regulation experiments, G418 was removed from the medium. The PC12 cell variants, GSrasDN6 expressing a dominant-negative mutant ras gene (15) under the transcriptional control of the mouse mammary tumor virus promoter, M-M17-26 expressing the Ha-ras Asn-17 gene under the transcriptional control of the mouse metallothionein-I promoter (7), and srcDN2 expressing the K295R mutant (kinase dead) form of chicken Src under the control of the cytomegalovirus promoter (8) were grown, as were PC12 cells, in DMEM supplemented with 10% fetal bovine serum and 5% horse serum. In a series of experiments involving dexamethasone treatment, the cells were placed in charcoal-treated serum 24 h before stimulation with 500 nM dexamethasone. To grow cells in suspension, PC12 cells were dispersed in 50 ml of complete medium at a density of 1 × 105 cells/ml in a 250-ml polycarbonate spinner flask (Corning) (18). The suspension was gently shaken at 37 °C on a rotary shaker in an incubator.

Binding Assays

Radioreceptor assays were carried out as described previously (11). The cells were grown on collagen (200 µg/ml)- and polylysine (10 µg/ml)-coated six-well plates (Costar). Cell culture monolayers were washed and equilibrated with fresh, serum-supplemented DMEM for 1 h. Total binding of growth factors was measured by adding saturating concentrations of 125I-EGF (0.5 × 106 cpm/ml) or 50-100 pM 125I-NGF (to measure high affinity p140trk receptors). Nonspecific binding was evaluated by adding a 100-fold excess of unlabeled growth factors to sister cultures and was typically 5-10% and 20-30% of total binding for EGF and NGF, respectively. The incubation, unless otherwise stated, was carried out at 37 °C for 45 min, then the incubation buffer was removed, and the cells were washed with ice-cold phosphate-buffered saline (138 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 1.5 mM KH2PO4). The cell monolayer was solubilized with 1 ml of 1 N NaOH overnight at room temperature. The cell-associated radioactivity was counted in a gamma -counter; a portion of the solubilized mixture was used for protein determination. Data points represent specific binding values and are the means of quadruplicate samples minus the nonspecific binding, expressed as counts/min/µg of protein (EGF) or counts/min/mg of protein (NGF) ± S.D. Binding experiments with cells grown in suspension were performed for 45 min in suspension, using 3 × 106 cells/ml of medium with 125I-EGF (1 × 106 cpm/ml) in the presence or absence of 10 µg/ml unlabeled EGF. The separation of free 125I-EGF was done by centrifuging the cells three times each for 10 min at 4 °C. Binding studies using plasma membrane preparations (11) were performed similarly at 4 °C, except that free and membrane-bound EGF were separated by Microfuge centrifugation (12,000 × g) at 4 °C using phosphate-buffered saline buffer containing 0.1% bovine serum albumin, pH 7.4. Down-regulation was performed by incubation of the cultures at 37 °C with either NGF (2 nM) or EGF (1 nM) for the period of time indicated. The monolayers were washed to remove the unbound growth factors, incubated in fresh DMEM for 2 h at 37 °C to allow internalization of remaining growth factor-receptor complexes (10, 11), and after two additional washes with medium, the extent of receptor down-regulation was estimated by the amount of 125I-growth factor associated with the cell. FGF binding was assessed as described above with the exception that the cultures were used 24 h after plating, and the radioreceptor assay was performed in 200 µl of binding buffer (DMEM containing 10 µl/ml heparin, 0.2% bovine serum albumin, 25 mM HEPES, pH 7.4) with 0.4 ng of either 125I-labeled acidic FGF or 125I-labeled basic FGF in the presence or absence of 50 ng of the respective unlabeled growth factor, as described previously (17). Binding was terminated with two washings with binding buffer followed by a third wash for 5 min with binding buffer at pH 7.5 or pH 4.0 for low and high affinity FGF binding, respectively (17).

Cell Labeling

For iodination of cell surface proteins, 3 × 106 cells grown on 10-cm collagen- and polylysine-coated tissue culture dishes were incubated with 1 mCi of Na125I and 0.2 mg/ml lactoperoxidase (19). In other experiments, PC12 cell cultures were incubated for 18 h in methionine-free DMEM containing 100 µCi/ml [35S]methionine/cysteine (Translabel; ICN, Plainview, NY). For immunoprecipitation of EGF receptors, the cell monolayers were washed twice with DMEM and solubilized for 30 min at 4 °C in radioimmune precipitation buffer (50 mM Tris-HCl, pH 7.4, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 1% deoxycholate, 1 mM phenylmethylsulfonyl fluoride, 1 mg/ml aprotinin) (11). Insoluble material was removed by centrifugation, and solubilized material was subjected to immunoprecipitation using anti-EGF receptor antibody.

Immunoprecipitation and Immunoblotting

Cells were plated in 10-cm tissue culture dishes 1 day prior to the experiment. Following treatment with growth factors, cells were washed twice with ice-cold Tris-buffered saline (20 mM Tris-HCl, pH 8.0, 137 mM NaCl) and subjected to lysis in 1 ml of 1% Nonidet P-40 in lysis buffer (20 mM Tris-HCl, 137 mM NaCl, 0.5 mM EDTA, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 0.15 unit/ml aprotinin, 20 mM leupeptin, 1 mM sodium vanadate) at 4 °C for 20 min. Insoluble material was removed by centrifugation for 10 min at 12,000 × g, and lysates were subjected to immunoprecipitation with anti-trkA or anti-Erk antibodies for 2 h at 4 °C with continuous agitation, followed by an additional 2-h incubation with protein A-Sepharose. Precipitates were washed three times with lysis buffer and once with water, then boiled for 5 min in SDS sample buffer (0.06 mM Tris-HCl, pH 6.8, 12.5% glycerol, 1.25% SDS, 5% beta -mercaptoethanol, 0.002% bromphenol blue), and subjected to SDS-PAGE on 7.5% polyacrylamide gels, followed by transfer to nitrocellulose. Blots were probed overnight at 4 °C with the primary antibodies and analyzed using an enhanced or Tropix chemiluminescence system and horseradish peroxidase-coupled secondary antibodies and quantitated by densitometry.

Kinase Assays

EGF-dependent tyrosine kinase activity was assayed in both whole cells and cell-free membrane fractions. PC12 cells were labeled for 4 h with [32P]orthophosphate (0.25 mCi/ml) in phosphate-free DMEM (16). For membrane experiments, 200 µg of PC12 cell membranes were preincubated with EGF (10 ng/ml) for 15 min at 37 °C in a reaction buffer containing 20 mM HEPES, pH 7.2, 0.5 mM MgCl2, 3 mM MnCl2, and 50 µM Na3VO4 in a final volume of 50 µl (13). The reaction was initiated by the addition of 2 µCi of [gamma -32P]ATP in 50 µM unlabeled ATP for 5 min at 4 °C. The reaction was terminated by the addition of SDS sample buffer, and the samples were analyzed by SDS-PAGE and autoradiography (11). In other experiments, the kinase activity of EGF receptors eluted with N-acetylglucosamine (300 mM) from wheat germ lectin-Sepharose chromatography (11) was evaluated in a similar way.

In Vitro Erk1 Kinase Assay

Washed protein A-agarose pellets containing immunoprecipitated Erk1 were suspended in 30 µl of kinase assay buffer (7.5 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM dithiothreitol, 2.5 µM protein kinase A inhibitor peptide PKI (6-22)-amide, 225 µM cold ATP, 25 µCi of [gamma -32P]ATP, 500 µg/ml MBP as kinase substrate) and incubated for 30 min at room temperature. The reaction was terminated by the addition of 30 µl of 2 × SDS sample buffer. Samples were heated for 5 min in a boiling water bath then electrophoresed through a 4-20% Tris-glycine gradient gel (NOVEX). Following electrophoretic resolution, radiolabeled proteins were transferred to polyvinylidene fluoride membranes. Phosphorylated MBP was visualized by exposure of the membranes to Biomax MR film (Eastman Kodak Co.). MBP-associated radioactivity was quantitated directly from the polyvinylidene fluoride membranes using an AMBIS radioanalytic imaging system and confirmed by scintillation counting of the excised bands.

Differentiation Assay

To evaluate neurite outgrowth, cells were plated at low density (1,000-5,000 cells/dish) on collagen- and polylysine-coated tissue culture dishes in the appropriate medium. The cells were treated for different periods of time with the indicated reagents, examined by light microscopy in an inverted Nikon-Diaphot microscope, and photographed at × 320 magnification.


RESULTS

NGF-induced Down-regulation of EGF Receptors

The level of 125I-EGF binding during NGF-induced differentiation of PC12 cells was examined (Fig. 1). Treatment of the cells with 50 ng/ml NGF progressively reduced the level of 125I-EGF binding; 50% reduction was seen after 3 days of treatment. In wild-type PC12 cells, this decrease in binding represents a decrease in EGF receptor level (Fig. 1, bottom) and accompanies the NGF-induced elongation of neurites (Fig. 1, top). The neuropeptide PACAP induces similar, but somewhat less robust neurite outgrowth in PC12 cells, but does not affect the binding of 125I-EGF (Fig. 2A). Staurosporine, a microbial protein kinase inhibitor, also induces rapid neurite outgrowth in PC12 cells, but, in contrast to NGF, increases 125I-EGF binding up to 3-fold (Fig. 2B). By way of comparison, NGF-induced differentiation of PC12 cells does not affect the level of either high or low affinity receptors for acidic or basic FGF (Table I) or of receptors for insulin-like growth factor I (20).


Fig. 1. Time course of NGF-induced down-regulation of EGF receptors in PC12 cells. PC12 cell cultures were grown in medium with 50 ng/ml NGF. The medium was changed, and fresh NGF was added every other day. Binding of 125I-EGF (0.2 × 106 cpm/1 × 105 cells) was measured by incubation for 45 min at 37 °C in the presence or the absence of excess unlabeled EGF (10-6 M). The error bars indicate the standard deviation. All points differ from 0 day with a p value of <0.05. The upper panel shows control PC12 cells and the typical neurite outgrowth induced by NGF after 76 and 120 h of treatment. The panel inset shows the Western blots of PC12 cell lysates obtained from control cultures (C) and cultures treated with 50 ng/ml NGF for 2 days (2d), 4 days (4d), and 6 days (6d) using the 1210 polyclonal anti-EGF receptor (arrow, 170 kDa) antibody.
[View Larger Version of this Image (65K GIF file)]



Fig. 2. Effect of PACAP and staurosporine on neurite outgrowth and 125I-EGF binding in PC12 cells. A, PC12 cells were treated for 4 days with either 50 ng/ml NGF (c), 20 nM PACAP (d), or left untreated (b). B, PC12 cells were treated for 60 h with either 50 ng/ml NGF (c), 50 nM staurosporine (d), or left untreated (b). The specific binding of 125I-EGF was measured as described under "Experimental Procedures." The error bars indicate the S.D. NGF differs from control in A with a p value <0.01 and in B with a p value of <0.05.
[View Larger Version of this Image (76K GIF file)]


Table I.

The effect of NGF treatment on the binding of fibroblast growth factors to PC12 cells

Untreated PC12 cells and PC12 cells treated for 7 days with NGF (50 ng/ml) were grown in 24-well plates coated with collagen/polylysine. The medium was changed, and fresh NGF was added every other day. Then the cells were washed twice with DMEM containing 20 mM HEPES, pH 7.5, and 0.1% bovine serum albumin. The cultures were incubated for 2 h at 4°C with 2 ng/ml of either 125I-labeled acidic or basic FGF in the same medium supplemented with 200 ng/ml heparin. The binding was stopped by washing the cells with fresh binding medium. To dissociate low affinity bound factor the cultures were incubated for 5 min in phosphate-buffered saline, pH 7.5, containing 25 mM HEPES and 2 M NaCl; to dissociate high affinity bound factor, the cultures were then incubated for another 5 min in phosphate-buffered saline, pH 4.0, containing 20 mM HEPES and 6 M NaCl (19). Nonspecific binding was measured in the presence of 200 ng/ml of the appropriate unlabeled FGF. The values represent the mean ± S.D. of three different experiments each performed in duplicate.


Treatment 125I-FGF specific binding
Acidic FGF
Basic FGF
High Low High Low

cpm/mg protein
Control 6,187  ± 200 7,287  ± 100 13,869  ± 250 11,065  ± 300
NGF 6,760  ± 120 6,586  ± 120 12,396  ± 400 13,313  ± 460

NGF-induced down-regulation of EGF receptors in PC12 cells can also be measured in isolated plasma membrane fractions derived from cells treated with NGF (Fig. 3A). Iodination of EGF receptors on PC12 cell membranes with lactoperoxidase and Na125I in control and 5-day NGF-treated cells, followed by immunoprecipitation of the labeled EGF receptors indicated a 98% decrease in receptor level (Fig. 3B). Another criterion of NGF-induced, down-regulation of EGF receptors would be a decrease in EGF-stimulated tyrosine kinase activity of EGF receptors. In both whole cells (Fig. 3C) and membrane fractions (Fig. 3D), phosphorylation of EGF receptors was very low or absent after 7 days of NGF treatment. When the levels of [35S]methionine-labeled, immunoprecipitated EGF receptors in control and 7-day NGF-treated PC12 cells were compared (Fig. 3E), 60 and 95% decreases in the level of 170- and 150-kDa EGF receptor proteins, respectively, were seen.


Fig. 3. Characteristics of NGF-induced down-regulation of EGF receptors in PC12 cells. A, NGF-induced down-regulation of EGF receptors as measured by binding assays with plasma membranes from PC12 cells treated with NGF for the indicated times. The error bars indicate the S.D. Inset, Western blotting with 1210 anti-EGF receptor antibody of 40 µg of membrane protein samples of control (C) and cells treated for 72 h with NGF. B, expression level of EGF receptors on control (C) and NGF-treated (5 days; 50 ng/ml) PC12 cells. PC12 cell cultures were iodinated as described under "Experimental Procedures," and 0.7 mg of each lysate was immunoprecipitated with 1210 anti-EGF receptor antibody (50 µg/ml). The immunoprecipitates were analyzed by 7.5% SDS-PAGE, and the resulting autoradiogram is presented. The positions of molecular mass markers are indicated on the left. C, untreated (C) and NGF-treated (7 days; 50 ng/ml) PC12 cells were labeled with [32P]orthophosphate (0.1 mCi/ml) for 4 h and incubated with EGF (10 ng/ml) for 10 min (+). Cell lysates (5 mg) were immunoprecipitated with 1210 anti-EGF receptor antibody (50 µg/ml), the immunoprecipitates were resolved on 7.5% SDS-PAGE, and the resulting autoradiogram is presented. D, untreated (C) and NGF-treated (7 days; 50 ng/ml) PC12 cell lysates were immunoprecipitated with 1210 anti-EGF receptor antibody (50 µg/ml), half the sample was incubated with [32P]ATP (left side), and the other half was resolved on 7.5% SDS-PAGE, immunoblotted with anti-phosphotyrosine antibody (1:10,000 dilution), and visualized by chemiluminescence (right side). E, analysis of [35S]methionine incorporation into EGF receptors in control (C) and NGF-treated (50 ng/ml; 7 days) PC12 cells. Cell lysates (0.5 mg) were immunoprecipitated with 1210 anti-EGF receptor antibody (50 µg/ml), the immunoprecipitates were resolved on 7.5% SDS-PAGE, and the resulting autoradiogram is presented. Both the intact 170-kDa and the proteolytically derived 150-kDa EGF receptor (EGFR) proteins are shown.
[View Larger Version of this Image (39K GIF file)]


NGF-induced Down-regulation of EGF Receptors Is p140trk-dependent

PC12 cells express two types of receptors for NGF: the high affinity receptor p140trk and the low affinity receptor p75NGFR (3). In PC12nnr5 cells, a PC12 variant that expresses p75NGFR, but very little p140trk (13), NGF does not induce neurite outgrowth. When human p140trk is transfected into PC12nnr5 cells, they grow neurites in response to NGF stimulation (21). Also, overexpression of p140trk in wild-type PC12 cells accelerated NGF-induced neurite outgrowth in the 6.24 PC12 cell variant (12).

To determine if NGF-induced down-regulation of EGF receptors is mediated by p140trk receptors, we first estimated the levels of NGF and EGF receptors in these several PC12 cell variants (Fig. 4). Indeed, compared with wild-type PC12 cells, PC12nnr5 cells express very low levels of p140trk receptors, but had 63% of the EGF receptors seen in the wild-type PC12 cells, while the 6.24 cell variant expressed 240 and 205% more p140trk and EGF receptors, respectively, than did the wild-type. The level of EGF receptors in PC12nnr5 cells was not altered, even after 7 days of NGF treatment as evaluated by binding (Fig. 5). However, the EGF receptors in these cells could be rapidly homologously down-regulated by exposure of the cells to EGF. This is a reversible process, as indicated by the reappearance of cell surface binding upon removal of EGF (Fig. 5).


Fig. 4. Binding characteristics of EGF and NGF receptors in different PC12 cell variants. Binding was measured by incubation of cell cultures (1 × 105 cells) for 45 min at 37 °C with either A, 125I-EGF (0.8 × 105 cpm/ml) or B, 125I-NGF (1.5 × 105 cpm/ml; 50-100 pM) in the presence or absence of excess unlabeled growth factors, and the specific binding was determined as described under "Experimental Procedures." The error bars indicate the S.D.
[View Larger Version of this Image (42K GIF file)]



Fig. 5. Time course of EGF binding to PC12nnr5 cells. The cells were treated for the indicated periods of time with 50 ng/ml NGF (bullet --bullet ) or 20 ng/ml EGF (open circle --open circle ), and binding assays were done as described under "Experimental Procedures." W, change of culture medium. The error bars indicate the S.D.
[View Larger Version of this Image (22K GIF file)]


PC12nnr5 cells were stably transfected with human p140trk as recently described (21). Out of 120 clones generated, a dozen were selected based on their expression of p140trk and EGF receptors and the ability of NGF treatment to down-regulate the EGF receptors. As indicated in Table II, four clones were further characterized. Clone 42 is a p140trk overexpressor, clones 61 and 106 have levels of p140trk similar to those in PC12 cells, and clone 50 expresses much lower levels of p140trk (Table II). These binding data are supported by the Western blots presented in Fig. 6, indicating different degrees of EGF receptor down-regulation in the four clones. This figure also shows that the transfected trk receptors are functional in that they mediate the stimulation of Erk phosphorylation by 50 ng/ml NGF (Fig. 6). The NGF-induced down-regulation of EGF receptors was measured in all four clones. No direct correlation was found between NGF-induced neurite outgrowth and NGF-induced down-regulation of EGF receptors (Table II). NGF does not down-regulate EGF receptors in PC12nnr5 cells, but does so (30-60% down-regulation) after introduction of p140trk into these cells (Table II). Therefore, it seems likely that NGF-induced down-regulation is mediated by p140trk. Support for this suggestion was also provided by experiments with K-252a (Fig. 7). K-252a, a specific inhibitor of NGF-induced p140trk tyrosine kinase activity in whole PC12 cells (22), prevented the down-regulation of EGF receptors by NGF in both parental PC12 cells (Fig. 7A) and 6.24 PC12 p140trk-overexpressing cells (Fig. 7B). Although the NGF-induced neurite outgrowth in 6.24 cells is accelerated as it is in PC12nnr5-p140trk.42 cells, the time course of NGF-induced down-regulation of EGF receptors is similar to that in wild-type PC12 cells (Fig. 1), reaching 50% decrease in receptor levels in about 48-72 h (Fig. 7B).

Table II.

NGF-induced neurite outgrowth and down-regulation of EGF receptors in PC12nnr5 cells stably transfected with human p140trk receptors


Clonea NGF-induced neurite outgrowthb 125I-NGF bindingc 125I-EGF bindingd
Control NGF

cpm/mg protein
42 Very fast (6-10 h), extensive sprouting, long, branched neurites 10,950  ± 1860 18.9  ± 1.7 8.2  ± 0.6
50 Delayed appearance (24 h), short neurites 1,750  ± 311 18.8  ± 2.1 12.0  ± 0.8
61 Delayed appearance (24 h), extensive sprouting 4,125  ± 330 17.8  ± 1.4 6.4  ± 0.6
106 Very fast (4-6 h), extensive sprouting of very long neurites 3,382  ± 642 36.1  ± 7.4 24.1  ± 4.2

a These clones were propagated for 3-4 months in culture and showed stable expression of p140trk protein, NGF-induced Erk phosphorylation activity, and NGF-induced neurite outgrowth.
b The percent of cells bearing neurites and the length of neurite outgrowth was estimated by light microscopy.
c The binding was performed as described under "Experimental Procedures" using 60 pM 125I-NGF to estimate only high affinity trkA receptors. These values represent the mean ± S.D. of four experiments each done in quadruplicate.
d The binding was performed as described in "Experimental Procedures," using untreated cultures or cultures treated with NGF (50 ng/ml) for 3 days.


Fig. 6. NGF-induced down-regulation of EGF receptors and stimulation of Erk phosphorylation in stably transfected PC12nnr-p140trk clones. The cultures were treated for 4 days with 50 ng/ml NGF to measure EGF receptor (EGFR) level (lower panel) or for 10 min to measure Erk phosphorylation. Erk phosphorylation was estimated by Western blotting using an antibody selective for phospho-Erk (upper panel). The paper was stripped and reprobed with anti-Erk1 antibody to measure the amount of Erk on the blot (middle panel). C, control; N, NGF.
[View Larger Version of this Image (40K GIF file)]



Fig. 7. The effect of K-252a on NGF-induced down-regulation of EGF receptors. A, PC12 cell cultures (2 × 105 cells/well) were treated with 0.01% dimethyl sulfoxide (bullet --bullet ), 200 nM K-252a (black-triangle-----black-triangle), 50 ng/ml NGF (open circle --open circle ), and 200 nM K-252a plus 50 ng/ml NGF (triangle --triangle ). B, 6.24 cell cultures (0.7 × 106 cells/well) were treated with 500 nM K-252a (black-triangle--black-triangle), 20 ng/ml NGF (open circle --open circle ), 5 ng/ml NGF (bullet --bullet ), and 500 nM K-252a plus 5 ng/ml NGF (triangle --triangle ). The medium was changed every day, and K-252a was preincubated with the cultures for 1 h before NGF addition. The cultures were washed twice with fresh medium before the binding experiments were performed. The error bars indicate the S.D. NGF differs from control at each point in A and from 0 day in B with a p value of <0.05.
[View Larger Version of this Image (16K GIF file)]


NGF-induced Down-regulation of EGF Receptors is Ras-dependent

To test whether NGF-induced down-regulation of EGF receptors is dependent upon Ras activation, two PC12 cell variants, transiently (GSrasDN6) or stably (M-M17-26) overexpressing the dominant-negative mutant RasN17 were employed. As shown in Fig. 4, these variants express different levels of p140trk and EGF receptors. Expression of the dominant-negative Ras protein is induced in GSrasDN6 and increased in M-M17-26 by treatment with dexamethasone (14, 15). To determine whether the dominant-negative Ras protein affects the stimulation of Erks under the conditions in which NGF-induced down-regulation was measured, we examined NGF- or EGF-induced phosphorylation of MBP by immunoprecipitated Erks in GSrasDN6 cells and NGF-induced phosphorylation of MBP by immunoprecipitated Erks in M-M17-26 cells compared with wild-type PC12 cells (Fig. 8C). In GSrasDN6 cells not treated with dexamethasone, NGF and EGF induced a 12- and 11-fold increase in Erk1 activity, respectively, measured by the phosphorylation of myelin basic protein (Fig. 8C). In dexamethasone-treated GSrasDN6 cells, the NGF- or EGF-induced increases in Erk1 activity were almost completely inhibited (Fig. 8C). Under identical conditions, a 25% reduction in 125I-EGF binding could be measured after 48 h of NGF treatment (Fig. 8A) or 4-5 days (data not shown) in GSrasDN6 cells not treated with dexamethasone (Fig. 8A). However, a complete homologous down-regulation of EGF receptors could be observed (Fig. 8A). Upon dexamethasone treatment, the small NGF-induced down-regulation effect was blocked, but not the EGF-induced homologous down-regulation of EGF receptors (Fig. 8A).


Fig. 8. NGF- and EGF-stimulated down-regulation of EGF receptors and activation of Erk1 GSrasDN6 and M-M17-26 dominant-negative ras cells. A, specific binding of 125I-EGF to GSrasDN6 cells cultured in the absence (-DEX) or the presence (+DEX) of dexamethasone (1 µM) for 24 h followed by an additional 48 h of incubation with either 50 ng/ml NGF (2, 5), 20 ng/ml EGF (3, 6), or no further additions (1, 4). B, 125I-EGF binding was performed as described under "Experimental Procedures" with M-M17-26 cell cultures untreated (open circles) or treated with 50 ng/ml NGF (filled circles) for 4 days. The error bars indicate the S.D. C, GSrasDN6 cells cultured in the absence (-DEX) or the presence (+DEX) of dexamethasone (1 µM) for 24 h, and M-M17-26 and PC12 cells were treated with 50 ng/ml NGF (N), 20 ng/ml EGF (E), or were left untreated (C). Erk1 was immunoprecipitated from clarified cell lysates (2.5 mg), and immune complex kinase assays using MBP as an exogenous substrate were performed as described under "Experimental Procedures." The fold activity increase was calculated by densitometer and was as follows: GSrasDN (-DEX): N, 11.8; E, 11.5; (+DEX): N, 2.0; E, 1.5; M-M17-26 cells: N, 0.7; E, 0.6; PC12 cells; N, 5.2; E, 6.6. The autoradiograms shown are from a single representative experiment and are characteristic of results obtained from three independent experiments.
[View Larger Version of this Image (25K GIF file)]


In M-M17-26 cells in which the dominant-negative RasN17 is stably overexpressed, neither NGF nor EGF stimulated Erk1-induced MBP phosphorylation (Fig. 8C). In these cells, NGF-induced heterologous down-regulation of EGF receptors is completely blocked (Fig. 8B), but the EGF-induced homologous down-regulation (100 in 1 h) is unaffected (data not shown).

NGF-induced Down-regulation of EGF Receptors is Src-dependent

The SrcDN2 PC12 cell variant, overexpressing a kinase-inactive, dominant-negative Src was treated with NGF and 125I-EGF binding was measured (Fig. 9). These cells express 46% of the p140trk and 86% of the EGF receptors seen in wild-type PC12 cells (Fig. 4). NGF treatment for 4 days did not induce the down-regulation of EGF receptors (Fig. 9) typical of wild-type PC12 cells. As expected, Western blotting analysis also did not show any change in the level of EGF receptors in SrcDN2 cells treated for 5 days with 50 ng/ml NGF compared with untreated cells. However, treatment of the cells with 50 ng/ml EGF for 1 h at 37 °C induced 86% homologous down-regulation of the EGF receptors (data not shown).


Fig. 9. Effect of dominant-negative Src on NGF-induced down-regulation of EGF receptors. Control (bullet --bullet ) and NGF-treated (50 ng/ml) SrcDN2 cell cultures grown on collagen- and polylysine-coated dishes were used for EGF binding as described under "Experimental Procedures." Error bars indicate the S.D.
[View Larger Version of this Image (17K GIF file)]


NGF-induced Down-regulation of EGF Receptors Is Independent of Neurite Outgrowth

In view of the observation that in wild-type PC12 cells, the NGF-induced down-regulation of EGF receptors is concomitant with NGF-induced neurite outgrowth, we cultured PC12 cells for 7 days either in monolayer or suspension (18) cultures in the presence or absence of 50 ng/ml NGF. In monolayer cultures the cells grow neurites in the presence of NGF; in suspension they aggregate, but do not grow neurites (18). Thereafter the cells were harvested and analyzed by Western blotting with either anti-EGF receptor antibody to measure EGF receptor down-regulation or anti-neurofilament-M antibody to measure the efficiency of the NGF treatment of the cells. As seen in Fig. 10, NGF induced down-regulation of EGF receptors in suspension cultures in the absence of neurite outgrowth after 7 or 10 days of NGF treatment. Binding experiments with 125I-EGF indicated a decrease of 68 and 82% in EGF receptors in suspension cultures treated for 7 and 10 days with NGF, respectively, compared with 85% decrease in EGF receptors in monolayer cultures.


Fig. 10. Western blotting analysis of EGF receptors (EGFR) and neurofilament M (NF-M) in PC12 cell cultures. The cultures, grown as monolayers or in suspension, were treated with NGF (N) (50 ng/ml) for seven (7d) or 10 (10d) days or left untreated (C). Fifty µg of each cell lysate were subjected to 7.5% SDS-PAGE and immunoblotted with the appropriate antibody.
[View Larger Version of this Image (29K GIF file)]



DISCUSSION

Both acute and chronic heterologous regulation of EGF receptors has been demonstrated in many cells. This regulation process is characterized by a change in either the affinity or the number of EGF receptors. For example, a decreased affinity of EGF receptors was measured upon treatment of cells with platelet-derived growth factor (23), vasopressin (24), interleukin 1 (25), and phorbol esters (26), and a decrease in the number of EGF receptors was observed in response to thyroid hormone (27), norepinephrine (28), nerve growth factor (11), or after infection with adenovirus (29, 30) or Rous sarcoma virus (31). In a few cases, the heterologous up-regulation of EGF receptors has been seen. An increased number of EGF receptors is evident in 3T3-L1 fibroblasts treated with 3-deazaadenosine (32), in teratocarcinoma cells treated with retinoic acid (33), or upon oncogenic transformation of carcinoma cells (34). The cellular signaling pathways utilized by G protein-coupled receptors, tyrosine kinase receptors, viruses, or drugs to regulate EGF receptors are as yet poorly characterized.

PC12 cells possess receptors for EGF, FGF, and NGF and have been used to investigate the process of heterologous down-regulation of EGF receptors by NGF. In these cells, both an acute (10 min) (35, 36), as well as a chronic (several days) (10, 11) down-regulation of EGF receptors in response to NGF has been reported. This biphasic down-regulation process was also observed upon NGF-induced down-regulation of c-neu receptors by NGF in PC12 cells (16). The present data emphasize the three major characteristics of the NGF-induced, chronic down-regulation of EGF receptors in PC12 cells: (a) a decrease in receptor level on the cell surface; (b) a disappearance of EGF-stimulated, receptor-mediated tyrosine kinase activity; and (c) a decrease in receptor synthesis.

Mechanisms have been proposed for the acute NGF-induced down-regulation of EGF receptors (35, 36). Acute regulation of EGF receptors has been attributed to activation of either protein kinase C, which phosphorylates threonine 654 of the EGF receptor (37), or of calmodulin-dependent protein kinase II, which phosphorylates serine 1046/1047 (38), or of other unknown kinases (39, 40), which might be also the case for PC12 cells. On the other hand, the signaling pathway(s) utilized by NGF for the chronic down-regulation of EGF receptors has not been addressed. The chronic, NGF-induced down-regulation of EGF receptors in PC12 cells is definitely different in mechanism from the acute down-regulation. It is selectively induced by p140trk receptors, but not by G protein-coupled PACAP receptors or drug (staurosporine)-induced neurite outgrowth. This process is not due to a change in receptor affinity (10, 11), receptor processing, or receptor internalization (11, 16). The lack of NGF-induced heterologous down-regulation of EGF receptors in PC12nnr5 cells, the partial reconstitution of the heterologous down-regulation in PC12nnr5-p140trk transfectants, and the ability of K-252a to block NGF-induced EGF receptor down-regulation support the concept that this effect is mainly mediated by the high affinity NGF receptor, p140trk, and not by the low affinity NGF receptor, p75NGFR. This conclusion is also supported by the ability of both Src and Ras dominant-negative forms to block this cellular process, since these two signal transduction pathways are initiated by binding of NGF to p140trk receptors, but not by binding of NGF to p75NGFR (5).

Src has been implicated, in PC12 cells, in calcium-stimulated signaling events (5, 6, 8) as well as in tyrosine phosphorylation of cytoskeletal proteins (41), either of which might also be involved in NGF-induced down-regulation of EGF receptors. Alternatively, since expression of the dominant-negative Src blocked the tyrosine phosphorylation of both Src homologous collagen protein and mitogen-activated protein kinases (5, 6), the inhibition of NGF-induced down-regulation of EGF receptors might simply reflect the blockade of the Ras signaling pathway. Because Fyn, Yes, and other tyrosine kinase members of the Src family could also be blocked by overexpression of the kinase-inactive Src (8), there is a possibility that these kinases, as well, may be involved in NGF-induced down-regulation of the EGF receptors.

One possible explanation of our findings is that Ras-Erk activity is an obligatory element in p140trk-mediated pathway required for chronic NGF-induced, down-regulation of EGF receptors, affecting an event such as phosphorylation of protein(s) involved in the transcription, translation, and/or post-translational modification of EGF receptors.

Alternatively, it is possible that Ras suppression of NGF-induced neurite outgrowth indirectly blocked NGF-induced down-regulation of EGF receptors. This possibility seems unlikely, however, because our data suggest a lack of correlation between NGF-induced down-regulation of EGF receptors and NGF-induced neurite outgrowth in different PC12 cell variants investigated: different agents, PACAP and staurosporine, induced neurite outgrowth but not down-regulation of EGF receptors, and in suspension where neurite outgrowth is not possible NGF treatment induces down-regulation of EGF receptors in the absence of neurite outgrowth.

Preliminary studies show a significant decrease in EGF receptor mRNA after treatment of cells with NGF for 5 days.2 Under comparable conditions, the stability of the mRNA is unchanged. These data indicate that at least part of the mechanism by which NGF down-regulates the EGF receptor is transcriptional, but further experiments are necessary to confirm and extend these observations.

In summary, our data are consistent with the signal transduction mechanism of p140trk receptors (4) and strongly suggest a series of NGF-induced, neurite outgrowth-independent, p140trk-Src-Ras phosphorylation events in the down-regulation of EGF receptors in PC12 cells.


FOOTNOTES

*   The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    Permanent address: Dept. of Pharmacology, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91010, Israel.
   Permanent address: Laboratory of Cell and Tissue Cultures, Institute of Biotechnology, Yerevan, 375056, Armenia.
par    To whom correspondence should be addressed: Section on Growth Factors, NICHD, National Institutes of Health, Bldg. 49, Rm. 5A64, 9000 Rockville Pike, Bethesda, MD 20892. Tel.: 301-496-4751; Fax: 301-402-2079.
1   The abbreviations used are: NGF, nerve growth factor; 6.24, a pheochromocytoma clone overexpressing human p140trk; PC12nnr5, a pheochromocytoma clone nonresponsive to nerve growth factor; GSrasDN6, dexamethasone-inducible, dominant-negative Ras PC12 variant cell line; M-M17-26, stable, dominant-negative Ras PC12 variant cell line; SrcDN2, stable, dominant-negative Src PC12 variant cell line; p140trk, high affinity nerve growth factor receptor; EGF, epidermal growth factor; PACAP, pituitary adenylate cyclase-activating peptide; K-252a, 8R*,9S*,11S*-(-)-9-hydroxy-9-methoxycarbonyl-8-methyl-2,3,9,10-tetrahydro-8,11-epoxy-1H,8H,11H-2,7beta ,11alpha -triazadibenzo(a, g)cycloocta(c,d,e)trindene-1-one; Src, pp60c-src cytoplasmic tyrosine kinase; Ras, a guanine nucleotide-binding protein; Erk, extracellular signal regulated kinase; MBP, myelin basic protein; PAGE, polyacrylamide gel electrophoresis; DMEM, Dulbecco's modified Eagle's medium; FGF, fibroblast growth factor.
2   M. Shibutani, Y. Katagiri, and G. Guroff, unpublished data.

ACKNOWLEDGEMENT

We thank Dr. Simon Halegoua for dominant-negative Src cells, Dr. Geoffrey Cooper for dominant-negative Ras cells, Dr. Lloyd Greene for PC12nnr5 cells, and Dr. David Kaplan for 6.24 cells.


REFERENCES

  1. Guroff, G. (1985) Cell Culture in the Neurosciences, pp. 245-271, Plenum Publishing Corp., New York
  2. Greene, L. A., and Tischler, A. S. (1976) Proc. Natl. Acad. Sci. U. S. A. 73, 2424-2428 [Abstract]
  3. Chao, M. V. (1992) Neuron 9, 583-593 [Medline] [Order article via Infotrieve]
  4. Kaplan, D. R., and Stephens, R. M. (1994) J. Neurobiol. 25, 1404-1417 [Medline] [Order article via Infotrieve]
  5. Keegan, K., and Halegoua, S. (1993) Curr. Opin. Neurobiol. 3, 14-19 [Medline] [Order article via Infotrieve]
  6. Kremer, N. E., D'Arcangelo, G., Thomas, S. M., DeMarco, M., Brugge, J. S., and Halegoua, S. (1991) J. Cell Biol. 115, 809-819 [Abstract]
  7. Szeberenyi, J., Cai, H., and Cooper, G. M. (1990) Mol. Cell. Biol. 10, 5324-5332 [Medline] [Order article via Infotrieve]
  8. Rusanescu, G., Qi, H., Thomas, S. M., Brugge, J. S., and Halegoua, S. (1995) Neuron 15, 1415-1425 [Medline] [Order article via Infotrieve]
  9. Huff, K., End, D., and Guroff, G. (1981) J. Cell Biol. 88, 189-198 [Abstract/Free Full Text]
  10. Chandler, C. E., and Herschman, H. R. (1983) J. Cell. Physiol. 114, 321-327 [Medline] [Order article via Infotrieve]
  11. Lazarovici, P., Dickens, G., Kuzuya, H., and Guroff, G. (1987) J. Cell Biol. 104, 1611-1621 [Abstract]
  12. Hempstead, B., Rabin, S. J., Kaplan, L., Reid, S., Parada, L. F., and Kaplan, D. R. (1992) Neuron 9, 883-896 [Medline] [Order article via Infotrieve]
  13. Green, S. H., Rydel, R. E., Connolly, J. L., and Greene, L. A. (1986) J. Cell Biol. 102, 830-843 [Abstract]
  14. Thomas, S. M., DeMarco, M., D'Arcangelo, G., Halegoua, S., and Brugge, J. S. (1992) Cell 68, 1031-1040 [Medline] [Order article via Infotrieve]
  15. Feig, L. A., and Cooper, G. M. (1988) Mol. Cell. Biol. 8, 3235-3243 [Medline] [Order article via Infotrieve]
  16. Oshima, M., Weiss, L., Dougall, W. C., Greene, M. I., and Guroff, G. (1995) J. Neurochem. 65, 427-433 [Medline] [Order article via Infotrieve]
  17. Zimmer, Y., Givol, D., and Yayon, A. (1993) J. Biol. Chem. 268, 7899-7903 [Abstract/Free Full Text]
  18. Fujita, K., Guroff, G., Yavin, E., Goping, G., Orenberg, R., and Lazarovici, P. (1990) Neurochem. Res. 15, 373-383 [Medline] [Order article via Infotrieve]
  19. Lebien, T. W., Boue, D. R., Bradley, J. G., and Kersey, J. H. (1982) J. Immunol. 129, 2287-2292 [Abstract/Free Full Text]
  20. Yakovchenko, E., Whalin, M., Movsesyan, V., and Guroff, G. (1996) J. Neurochem. 67, 540-548 [Medline] [Order article via Infotrieve]
  21. Loeb, D. M., and Greene, L. A. (1993) J. Neurosci. 13, 2919-2929 [Abstract]
  22. Koizumi, S., Contreras, M. L., Matsuda, Y., Hama, T., Lazarovici, P., and Guroff, G. (1988) J. Neurosci. 8, 715-721 [Abstract]
  23. Olwin, B. B., and Hauschka, S. D. (1988) J. Cell Biol. 107, 761-769 [Abstract]
  24. Rozengurt, E., Brown, K. D., and Pettican, P. (1981) J. Biol. Chem. 256, 716-722 [Free Full Text]
  25. Bird, T. A., and Saklatvala, J. (1990) J. Biol. Chem. 265, 235-240 [Abstract/Free Full Text]
  26. Shoyab, M., DeLarco, J. E., and Todaro, J. (1979) Nature 279, 387-391
  27. Mukku, V. R. (1984) J. Biol. Chem. 259, 6543-6547 [Abstract/Free Full Text]
  28. Cruise, J. L., Coteccina, S., and Michalopoulos, G. (1986) J. Cell. Physiol. 127, 39-44 [Medline] [Order article via Infotrieve]
  29. Hoffman, P., Yaffe, M. B., Hoffman, B. L., Yei, S., Wold, W. S., and Carlin, C. (1992) J. Biol. Chem. 267, 13480-13487 [Abstract/Free Full Text]
  30. Boulukos, K. E., and Ziff, E. B. (1993) Oncogene 8, 237-248 [Medline] [Order article via Infotrieve]
  31. Wasilenko, W. J., Shawrer, L. R., and Weber, M. J. (1987) J. Cell Physiol. 131, 450-457 [Medline] [Order article via Infotrieve]
  32. McCaffrey, P. G., Friedman, B., and Rosner, M. R. (1984) J. Biol. Chem. 259, 12502-12507 [Abstract/Free Full Text]
  33. Rees, A. R., Adamson, E. D., and Graham, C. F. (1979) Nature 281, 309-311 [Medline] [Order article via Infotrieve]
  34. Gullick, W. J., Marsden, J. J., Whittle, N., Ward, B., Bobrow, L., and Waterfield, M. D. (1986) Cancer Res. 46, 285-292 [Abstract]
  35. Brown, A. B., and Carpenter, G. (1991) J. Neurochem. 57, 1740-1749 [Medline] [Order article via Infotrieve]
  36. Mothe, I., Ballotti, R., Tartare, S., Kowalski-Chauvel, A., and Van Obberghen, E. (1993) Mol. Biol. Cell 4, 737-746 [Abstract]
  37. Davis, R. J. (1988) J. Biol. Chem. 263, 9462-9469 [Abstract/Free Full Text]
  38. Countaway, J. L., Nairn, A. C., and Davis, R. J. (1992) J. Biol. Chem. 267, 1129-1140 [Abstract/Free Full Text]
  39. Countaway, J. L., Girones, N., and Davis, R. J. (1989) J. Biol. Chem. 264, 13642-13647 [Abstract/Free Full Text]
  40. Bird, T. A., and Saklatvala, J. (1989) J. Immunol. 142, 126-133 [Abstract/Free Full Text]
  41. Khan, M. A., Okumura, N., Okada, M., Kobayashi, S., and Nakagawa, H. (1995) FEBS Lett. 31, 201-204

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.